{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:59:46Z","timestamp":1772643586141,"version":"3.50.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"\n Objective<\/jats:title>\n This study aimed to evaluate national trends in amounts, prescription volumes, and the rationality of drug use in pharmacoeconomics associated with small molecule targeting inhibitors for lung cancer treatment among adult patients in China from 2016 to 2022.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Prescription data for outpatients diagnosed with lung cancer were extracted from the Hospital Prescription Analysis Cooperative Project database, covering hospitals across six major regions of 77 hospitals. Annual trends in prescription volumes and associated expenditures were analyzed. Additionally, pharmacoeconomic indicators related to small molecule targeting inhibitors were assessed to evaluate cost-effectiveness and utilization patterns. Demographic profiles, regional sources of patients, and classification of small molecule targeting inhibitors were examined.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Prescription volumes and amounts for small molecule targeting inhibitors in lung cancer treatment have increased annually. Since 2020, expenditure levels have stabilized. Furthermore, their use is supported by pharmacoeconomic evidence indicating rational and efficient medication utilization. There was a statistically significant increase in total prescriptions (P\n 1<\/jats:sub>\n &lt; 0.001) and overall medication expenditures (P\n 2<\/jats:sub>\n &lt; 0.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Between 2016 and 2022, the prescription volume of small molecule targeted inhibitors for lung cancer rose yearly, showing their expanding clinical use. Since 2020, despite continued growth in prescriptions, drug costs have stabilized or slightly decreased. This reflects that China\u2019s medical insurance negotiation and centralized procurement policies have effectively reduced patients\u2019 economic burden without limiting their access to these inhibitors. Pharmacoeconomic indicators also confirm that the use of these drugs has been both reasonable and efficient, allowing for increased drug utilization while reducing patients\u2019 financial strain.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fphar.2025.1700389","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:20:04Z","timestamp":1762503604000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A retrospective analysis of small molecule targeting inhibitor usage for lung cancer among outpatients in six major regions of China (2016\u20132022)"],"prefix":"10.3389","volume":"16","author":[{"given":"Bo","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu-Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Li","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijsu.2019.08.006","article-title":"Albumin-to-alkaline phosphatase ratio as a novel prognostic indicator for patients undergoing minimally invasive lung cancer surgery: propensity score matching analysis using a prospective database","volume":"69","author":"Abu-Talib","year":"2019","journal-title":"Int. J. Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1021\/acs.jmedchem.7b01310","article-title":"Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer","volume":"61","author":"Chen","year":"2018","journal-title":"J. Med. Chem."},{"key":"B3","first-page":"1","article-title":"Guidelines for the diagnosis and treatment of primary lung Cancer(2022 edition)","volume":"19","author":"Chen","year":"2022","journal-title":"Chin. J. Ration. Drug Use"},{"key":"B4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-025-02285-y","article-title":"NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer","volume":"24","author":"Dai","year":"2025","journal-title":"Mol. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"217001","DOI":"10.1016\/j.canlet.2024.217001","article-title":"Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: a retrospective cohort study","volume":"596","author":"Fletcher","year":"2024","journal-title":"Cancer Lett."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1111\/cas.15777","article-title":"Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer","volume":"114","author":"Goto","year":"2023","journal-title":"Cancer Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/cncr.35094","article-title":"Association between treatment and improvements in overall survival of patients with advanced\/metastatic non-small cell lung cancer since 2011: a study in the United States, Canada, and Germany using retrospective real-world databases","volume":"130","author":"Griesinger","year":"2024","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11523-021-00839-w","article-title":"Osimertinib: a review in previously untreated, EGFR mutation-positive, advanced NSCLC","volume":"16","author":"Lamb","year":"2021","journal-title":"Target Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3892\/ol.2014.2717","article-title":"Lung cancer and concurrent or sequential lymphoma: two case reports with hypersensitivity to bevacizumab and a review of the literature","volume":"9","author":"Pezzuto","year":"2015","journal-title":"Oncol. Lett."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1111\/cas.16192","article-title":"Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: current knowledge of genetic changes and molecular mechanisms","volume":"115","author":"Shiba-Ishii","year":"2024","journal-title":"Cancer Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"217455","DOI":"10.1016\/j.canlet.2025.217455","article-title":"RET-AREAL: a multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR\/ALK-TKIs","volume":"612","author":"Tang","year":"2025","journal-title":"Cancer Lett."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/cncr.34755","article-title":"Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: a systematic review and meta-analysis","volume":"129","author":"Wu","year":"2023","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1146\/annurev-med-051718-013524","article-title":"Precision management of advanced non-small cell lung cancer","volume":"71","author":"Yang","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semcancer.2020.07.009","article-title":"Precision medicine in non-small cell lung cancer: current applications and future directions","volume":"84","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1700389\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:20:07Z","timestamp":1762503607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1700389\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":15,"alternative-id":["10.3389\/fphar.2025.1700389"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1700389","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1700389"}}